Epinephrine is the first treatment for anaphylaxis. To investigate the clinical features of pediatric anaphylaxis, including the rate of using epinephrine and prescribing epinephrine auto-injector.
We performed a retrospective study in in-patients, out-patients, and emergency department visitors, who were under 15 years old, at Soonchunhyang University Hospital, Cheonan, Korea, from Jan. 2013 through Dec. 2014. A total of 68 patients were diagnosed with anaphylaxis by criteria at the time.
The causes of anaphylaxis were food (77.9%), drug (10.3%) and idiopathic (11.8%). The involved organs were cutaneous (88.2%), respiratory (80.9%), cardiovascular (20.6%), and gastrointestinal tract (14.7%). Patients were treated with systemic steroid (92.6%), anti-histamine (88.2%) and epinephrine (76.5%). 53 (77.9%) patients re-visited our pediatric allergy clinic and epinephrine auto-injectors were prescribed for 25 (36.8%) patients.
Epinephrine was not used in more than 20% and epinephrine auto-injectors were not prescribed for more than 60% of pediatric anaphylaxis patents. Physicians should make an effort to use epinephrine as the initial treatment of anaphylaxis and to prescribe epinephrine auto-injector.